NASDAQ · IMNM
Immunome, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IMNM: Nov 5, 2026
Immunome, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.67. The reported EPS for the same quarter last year was $-0.65.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.67 | $-0.64 | $-0.76 | 7 |
| Dec 2026 | $-0.68 | $-0.57 | $-0.82 | 7 |
| Mar 2027 | $-0.67 | $-0.61 | $-0.71 | 4 |
| Jun 2027 | $-0.80 | $-0.67 | $-1.05 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · The Motley Fool · Zacks- Fintel · Oct 16, 9:26 PM EDTWilliam Blair Initiates Coverage of Immunome at OutperformFintel reports that on October 16, 2026, William Blair initiated coverage of Immunome (NASDAQCM:IMNM) with a Outperform recommendation. Prior to this rating action, the stock closed at $17.40 on October 15, 2026. On October 16, 2026, the stock recorded a latest close of $16.47. O
- RTTNews · Oct 15, 10:35 AM EDTImmunome's Varegacestat: Could It Become The Second FDA-Approved Desmoid Tumor Treatment?(RTTNews) – Desmoid tumors, also known as aggressive fibromatosis, are rare soft-tissue tumors that do not spread to distant parts of the body but can recur. The tumors can cause severe pain, deformity and, in some cases, life-threatening organ damage, significantly affecting pat
- Fintel · Oct 1, 7:28 PM EDTStifel Initiates Coverage of Immunome with Hold RatingFintel reports that on October 1, 2026, Stifel initiated coverage of Immunome (NASDAQCM:IMNM) with a Hold recommendation.On the rating action date of October 1, 2026, the latest close for the stock was $20.89, while the pre-action close on September 30, 2026, was $21.51. The pric
- RTTNews · Sep 30, 9:42 AM EDTImmunome Gets FDA IND Clearance For IM-1340, Plans Phase 1 Trial In Solid Tumors(RTTNews) – Immunome, Inc. (IMNM), a clinical-stage oncology company, announced Wednesday that the U.S. FDA has cleared its Investigational New Drug (IND) application for IM-1340, an investigational antibody-drug conjugate, or ADC being developed for patients with advanced solid
- RTTNews · Sep 30, 8:11 AM EDTImmunome's IM-1340 Receives FDA IND Clearance For Advanced Solid Tumors(RTTNews) – Immunome, Inc. (IMNM), a clinical-stage targeted oncology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340, a potential first-in-class antibody-drug conjugate (ADC) for treating
- RTTNews · Aug 20, 4:21 AM EDTBiotech Stocks At 52-Week Highs – MRNA Surges +176% On Phase 3 Data, SCTV, MRVI, SOPH, IMNM(RTTNews) – The following biotech stocks reached a 52-week high on August 19, 2026, primarily driven by positive clinical research results and promising quarterly reports.
- The Motley Fool · Jul 12, 5:04 PM EDTWhat This Immunome Sale Means a Day Before a Big FDA MilestoneAn Immunome insider sold 100,000 shares for $2.4 million based on weighted average prices on July 6, 2026 and July 7, 2026.
- Zacks · Jul 10, 10:40 AM EDTImmunome Stock Up 32% in a Month: Here's What You Should KnowIMNM jumps 32% in a month. This comes as the FDA accepts varegacestat's NDA for desmoid tumors, with an approval decision expected by April 2027.
- Zacks · Jun 5, 10:54 AM EDT4 Biotech Stocks Investors Should Watch in 2026New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.
- Fintel · May 28, 1:25 PM EDTBarclays Initiates Coverage of Immunome (IMNM) with Overweight RecommendationFintel reports that on May 28, 2026, Barclays initiated coverage of Immunome (NasdaqCM:IMNM) with a Overweight recommendation. Analyst Price Forecast Suggests 62.62% Upside
- Zacks · May 6, 7:45 AM EDTTechne (TECH) Misses Q3 Earnings and Revenue EstimatesTechne (TECH) delivered earnings and revenue surprises of -2.75% and -2.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 5, 5:15 PM EDTExelixis (EXEL) Tops Q1 Earnings EstimatesExelixis (EXEL) delivered earnings and revenue surprises of +15.55% and -0.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Immunome, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.